Weight Gain and Adipose Tissue
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 1/11/2019 |
| Start Date: | April 2016 |
| End Date: | December 2018 |
Pilot Study to Examine the Effects of Weight Gain on Adipose Tissue
This study aims to examine the role of weight gain in adipose tissue immune cell influx and
development of obesity related cardiometabolic disorders. Adipose tissue-mediated chronic
systemic inflammation is implicated in the development of cardiometabolic disorders in
obesity. Therefore, resolution of adipose tissue inflammation may be key to ameliorating
obesity-associated dyslipidemia, insulin-resistance, and cardiovascular disease.
Proinflammatory cytokines contribute to the initial influx of immune cells into adipose
tissue during weight gain. However, mechanisms regulating these cytokines in the adipose
tissue milieu and the effects of weight gain on adipose tissue are not completely understood.
The study proposes to investigate the molecular events contributing to increased infiltration
of macrophages and T-cells into adipose tissue during weight gain. The central hypothesis is
that in lean subjects (with low body fat mass), healthy fat gain which is associated with
decreased expression of proinflammatory cytokines. However, in obesity (high body fat mass),
adipose tissue is altered, which permits increased expression of inflammatory cytokines and
further fat gain results in influx of immune cells. To test the hypothesis, adipose tissue
from well characterized lean (control, with low body fat) and obese individuals (with high
body fat) at baseline and after a modest 5% weight gain will be used. Adipose tissue samples
after subsequent weight loss will also be examined.
For this study, obesity will be defined by body composition rather than body mass index
(BMI), as several studies have shown that BMI does not adequately define obesity and several
individuals with normal BMI may indeed have high body fat mass. Individuals with body fat
content ≤25% for men, & <35% for women) will be considered lean and individuals with body fat
content >25% for men, ≥35% for women will be considered obese.
development of obesity related cardiometabolic disorders. Adipose tissue-mediated chronic
systemic inflammation is implicated in the development of cardiometabolic disorders in
obesity. Therefore, resolution of adipose tissue inflammation may be key to ameliorating
obesity-associated dyslipidemia, insulin-resistance, and cardiovascular disease.
Proinflammatory cytokines contribute to the initial influx of immune cells into adipose
tissue during weight gain. However, mechanisms regulating these cytokines in the adipose
tissue milieu and the effects of weight gain on adipose tissue are not completely understood.
The study proposes to investigate the molecular events contributing to increased infiltration
of macrophages and T-cells into adipose tissue during weight gain. The central hypothesis is
that in lean subjects (with low body fat mass), healthy fat gain which is associated with
decreased expression of proinflammatory cytokines. However, in obesity (high body fat mass),
adipose tissue is altered, which permits increased expression of inflammatory cytokines and
further fat gain results in influx of immune cells. To test the hypothesis, adipose tissue
from well characterized lean (control, with low body fat) and obese individuals (with high
body fat) at baseline and after a modest 5% weight gain will be used. Adipose tissue samples
after subsequent weight loss will also be examined.
For this study, obesity will be defined by body composition rather than body mass index
(BMI), as several studies have shown that BMI does not adequately define obesity and several
individuals with normal BMI may indeed have high body fat mass. Individuals with body fat
content ≤25% for men, & <35% for women) will be considered lean and individuals with body fat
content >25% for men, ≥35% for women will be considered obese.
Inclusion Criteria
- Age: 18 to 40 (inclusive) years
- BMI 18.5 <30 kg/m2
- Gender: Both males and females will be allowed to participate in the study
- Predominantly sedentary
- Absence of any chronic medical conditions other than seasonal or environmental
allergies
- On no prescription medications other than second generation antihistamines (cetirizine
, Fexofenadine, Desloratadine, Loratadine, etc), oral contraceptive pills, or
intrauterine devices
- Not a current smoker or tobacco user
- Not pregnant or breast feeding and not intending to become pregnant or breast feed
- Lean (low body fat mass) (body fat content ≤ 25% for men, < 35% for women) n=7; Obese
(high body fat mass) (body fat content >25% for men, ≥ 35% for women) n=7
- Ability to provide written informed consent
Exclusion Criteria
- Vulnerable study population will be excluded
- Presence of chronic diseases such as diabetes, and cardiovascular disease
- Pregnancy
- Anemic (hemoglobin <13.5 g/dL for men and <12.0 g/dL for women)
- Postmenopausal
- Smoking
- Use of chronic Medications (aspirin, statin, anti-inflammatory drugs)
- Subjects found to have significant sleep disorders will be excluded
- Dietary restrictions including lactose intolerance, and vegan diet
- Eating disorders that may interfere with weight gain and weight loss
We found this trial at
2
sites
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
Click here to add this to my saved trials